Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
Sacituzumab govitecan plus pembrolizumab led to significantly longer progression-free survival than chemotherapy plus pembrolizumab among patients with previously untreated, PD-L1-positive, advanced triple-negative breast cancer. (Funded by Gilead Sciences; ASCENT-04/KEYNOTE-D19 ClinicalTrials.gov number, NCT05382286.).
Authors
- E. de Azambuja
- Bernardo Leon Rapoport (ORCID: https://orcid.org/0000-0001-7610-3653)
- Clinton Yam (ORCID: https://orcid.org/0000-0002-0809-0851)
- Wassim McHayleh
- D Cescon
- C. Lai
- Lu Wang (ORCID: https://orcid.org/0000-0003-2617-655X)
- Dianna Gary
- Kevin Kalinsky
- Javier Salvador Bofill
- Manuel Alejandro Lara Bañuelas
- Sara M Tolaney
- Maryam Afshari
- Sherene Loi
- Peter Schmid
- Seock-Ah Im
- Sung-Bae Kim
- Ruffo Freitas-Junior
- Junichiro Watanabe
Institutions
- Ulsan College (KR)
- University Health Network (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Harvard University (US)
- Autonomous University of Chihuahua (MX)
- Emory University (US)
- The University of Melbourne (AU)
- Queen Mary University of London (GB)
- Peter MacCallum Cancer Centre (AU)
- Cancer Institute (WIA) (IN)
- Asan Medical Center (KR)
- Institut Jules Bordet (BE)
- Institut Gustave Roussy (FR)
- Princess Margaret Cancer Centre (CA)
- Seoul National University Hospital (KR)
- Juntendo University (JP)
- University of Ulsan (KR)
- Florida Hospital Cancer Institute (US)
- The Medical Oncology Centre of Rosebank (ZA)
- Hospital Araújo Jorge (BR)
- Dana-Farber Cancer Institute (US)
- Gilead Sciences (United States) (US)
- Hospital Universitario Virgen del Rocío (ES)
- University of Pretoria (ZA)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1056/nejmoa2508959
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 120.98